Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.49 |
| ▸ | MMP9 | P14780 | 7/20 | 0.49 |
| ▸ | MMP8 | P22894 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.45 |
| ▸ | NRP1 | O14786 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 2/20 | 0.44 |
| ▸ | MMP14 | P50281 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2808395 | 1.00 | MMP2 (0.49) | MMP2MMP9MMP8CA1CA2 | |
| SCHEMBL2807924 | 0.88 | MMP9 (0.52) | MMP2MMP9MMP8CA1CA2 | |
| SCHEMBL2807923 | 0.88 | MMP9 (0.52) | MMP2MMP9MMP8CA1CA2 | |
| SCHEMBL13128305 | 0.88 | L3MBTL1 (0.49) | MMP2MMP9MMP8CA1CA2 | |
| SCHEMBL30299102 | 0.86 | MMP9 (0.65) | MMP2MMP9MMP8CA1CA2 | |
| SCHEMBL2805413 | 0.84 | MMP9 (0.48) | MMP2MMP9MMP8CA1CA2 | |
| SCHEMBL2805419 | 0.84 | MMP9 (0.48) | MMP2MMP9MMP8CA1CA2 | |
| SCHEMBL25352953 | 0.84 | MMP2 (0.50) | MMP2MMP9MMP8CA1CA2 | |
| SCHEMBL25352949 | 0.84 | MMP2 (0.50) | MMP2MMP9MMP8CA1CA2 | |
| SCHEMBL2812796 | 0.83 | MMP2 (0.47) | MMP2MMP9MMP8CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2125757-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008101665-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | MMP2 161/4885MMP9 224/4885MMP8 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.